Al-Ola Abdallah/LinkedIn
May 1, 2025, 10:25
Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy
Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared an article by on X:
“Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.
- TPO-RAs did not increase the rate of thrombocytopenia resolution relative to supportive care.
- Adverse effects requiring therapy modification related to TPO-RAs occurred in 25% of patients.
- The financial toxicity associated with TPO-RAs was roughly $87,000.”
Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.
Authors: Jennifer Collins, Sarvnaz Sadrameli
You can Read the Full Article on Journal of Transplantation and Cellular Therapy.
More posts featuring Al-Ola A Abdallah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 1, 2025, 15:20
May 1, 2025, 14:51
May 1, 2025, 14:30
May 1, 2025, 14:00
May 1, 2025, 13:26
May 1, 2025, 13:03
May 1, 2025, 12:22